Journal: Frontiers in Neuroscience

Article Title: Neural Transplants From Human Induced Pluripotent Stem Cells Rescue the Pathology and Behavioral Defects in a Rodent Model of Huntington’s Disease

doi: 10.3389/fnins.2020.558204

Figure Lengend Snippet: Results of behavioral assessment in the 1231A3-NPC TP, fibroblast TP, and sham groups after TP into the QA-lesioned rat model. (A) Staircase test. (B) Rotarod test. (C) Stepping test. (D) Apomorphine-induced rotation test. (E) Cylinder test. n = 10, 9, and 9 in the 1231A3-NPC TP group, fibroblast TP group, and sham group, respectively. [1231A3-NPC TP vs. fibroblast TP ( # p < 0.05; ## p < 0.001), 1231A3-NPC TP vs. sham (* p < 0.05; ** p < 0.001)]. NPCs, neural precursor cells; TP, transplantation; QA, quinolinic acid.

Article Snippet: Next, 2 μl of human foreskin fibroblasts [BJ-1, 200,000 cells, American Type Culture Collection (ATCC), Manassas, VA, United States; CRL-2522] was injected in the fibroblast group, and 2 μl of suspension media was injected in the sham group.

Techniques: Transplantation Assay

Journal: bioRxiv

Article Title: AURKA inhibition amplifies DNA replication stress to foster WEE1 kinase dependency and synergistic antitumor effects with WEE1 inhibition in cancers

doi: 10.1101/2025.05.28.656693

Figure Lengend Snippet: A and B , Dose-response curves for determining the sensitivity of various human cancer cell lines to either adavosertib ( A ) or VIC-1911 ( B ) with multiple dose range (adavosertib: 0.0625-10 μmol/L; VIC-1911: 0.0313-2.5 μmol/L). Cell viability was determined after 4-day exposure to drugs by CellTiter-Glo assay. Cell viability was normalized to control cells. Data are shown as mean ± SEM. C and D , Representative images of cooperative correlation matrix (right) and Loewe plots (left) of HNSCC CAL27 cells ( C ) and NSCLC NCI-H520 cells ( D ) in combinational treatment VIC-1911/adavosertib. E , Status of TP53 mutation, Loewe synergy scores (LSS) and maximum synergistic area scores (LMSAS) of human cancer cell lines are shown for evaluating synergy of combinational VIC-1911 and adavosertib treatment using SynergyFinder. and synergy score >10 and red area indicate synergism. F and G , Dose-response curves of NHTBE ( F ) and BJ1 ( G ) cells treated with control, adavosertib, VIC-1911 or combination from 4-day CellTiter-Glo assay. Cell viability was normalized to control cells. Shown are the means of technical triplicates from one experiment and the data as shown mean ± SEM are representative of three independent experiments with consistent results.

Article Snippet: HNSCC (FaDu, Detroit 562, CAL27, SCC25, and SCC-9), lung cancer (NCI-H520, NCI-H358, NCI-H1437, A549, NCI-H441, NCI-H23 and NCI-H1792), ovarian cancer (A2780 and SK-OV3), pancreatic cancer (MiaPaCa-2), hepatocellular carcinoma (HepG2), and normal human fibroblast BJ1 cell lines were purchased from the American Type Culture Collection (ATCC); HNSCC SCC61 cell line was purchased from Sigma-Aldrich; the UNC7 is a patient-derived cancer cell line ( kind gift of Wendell Yarbrough, University of North Carolina ) and PCI-13 isogenic cell lines of differing TP53 including WT, null, G245D, C238F or R273H genotypes were kindly provided by Jeffrey Myers (MD Anderson Cancer Center).

Techniques: Glo Assay, Control, Mutagenesis